WHO ICTRP trial
A first-in-human dose escalation and expansion study with the SIRPa-directed…
NL-OMON56086 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON56086 |
|---|---|
| Public title | A first-in-human dose escalation and expansion study with the SIRPa-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin*s Lymphoma (NHL) |
| Scientific title | A first-in-human dose escalation and expansion study with the SIRPa-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin*s Lymphoma… |
| Primary sponsor | Byondis Bv. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Netherlands |
| Conditions | lymphoma NHS Non-Hodgkin Lymphoma;10025322 |
| Interventions | BYON4228 will be given by intravenous infusion. Different doses of BYON4228 will be given to different patients. The first patient will receive the lowest dose 7 mg and will be escalated for the following patients as presented in Table 2… |
| Registration date | Dec 22, 2022 |
| Target size | 8 |
| Secondary IDs | CTIS2024-512390-27-00;EUCTR2022-002018-18-NL;NL82832.091.22 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: